These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15171051)

  • 1. [Docetaxel and non-small cell lung cancer].
    Le Guen Y; Le Cesne A
    Bull Cancer; 2004 Mar; 91(3):263-70. PubMed ID: 15171051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
    Ornstein DL; Nervi AM; Rigas JR
    Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
    Belani CP;
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
    Morere JF
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
    [No Abstract]   [Full Text] [Related]  

  • 9. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
    Ardizzoia A; Acquati M; Fagnani D; Giordano M; Visini M; Scanni A; Quattrone A; Fusco O; Vergani C; Casartelli C; Tagliabue P; Malugani F;
    Lung; 2004; 182(1):1-8. PubMed ID: 14752667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
    Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation in locally advanced non-small cell lung cancer.
    Bonomi P; Shirazi W
    Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
    [No Abstract]   [Full Text] [Related]  

  • 14. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 15. [The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?].
    Grossi F; de Marinis F; Frontini L; Gridelli C
    Tumori; 2008; 94(3):5-14. PubMed ID: 18705422
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
    Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
    Waters JS; O'Brien ME
    Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.